omniture
I-Mab-天境生物科技(上海)有限公司

Latest News

I-Mab Biopharma and TRACON Pharmaceuticals Announce Dosing of the First Patient in a Phase 1 Trial of the CD73 Antibody TJD5 in the U.S. in Patients with Advanced Solid Tumors

SHANGHAI and SAN DIEGO, Aug. 1, 2019 /PRNewswire/ -- I-Mab Biopharma (I-Mab), a China and U.S.-base...

2019-08-01 20:06 1484

MacroGenics and I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China

ROCKVILLE, Md. and SHANGHAI, July 10, 2019 /PRNewswire/ -- MacroGenics, Inc. (NASDAQ: MGNX), a clin...

2019-07-11 04:01 1649

I-Mab Announces Dosing of First Patient in a Phase I Clinical Trial of TJC4, a Potentially Differentiated CD47 Antibody, for the Treatment of Cancers in the United States

GAITHERSBURG, Md., June 25, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a clinical stage biotec...

2019-06-25 22:01 1101

I-Mab Biopharma and WuXi Biologics Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs

SHANGHAI, April 16, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a biotech company focusing excl...

2019-04-16 20:39 841

I-Mab Biopharma Signs Agreement for Clinical Research of TJD5 in Combination Therapy

SHANGHAI, April 10, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a clinical stage biopharmaceuti...

2019-04-11 10:34 298

I-Mab Biopharma and Jiangsu Nhwa Pharmaceutical Announce Strategic Collaboration Agreement with Biodextris and a Boston-Based, Leading Academic Medical Center

BOSTON, April 8, 2019 /PRNewswire/ -- I-Mab Biopharma (I-Mab), a clinical stage biotech company bas...

2019-04-08 09:01 429

I-Mab Biopharma and MorphoSys Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma

SHANGHAI, March 19, 2019 /PRNewswire/ -- I-Mab Biopharma (I-Mab), a China-based clinical stage biop...

2019-03-20 05:05 309

I-Mab Biopharma Announces Dosing of First Subject in Phase 1 Clinical Trial of Anti-GM-CSF Monoclonal Antibody TJM2 in the United States

ROCKVILLE, Md., March 19, 2019 /PRNewswire/ -- I-Mab Biopharma (I-Mab), a China -based clinical stag...

2019-03-19 18:00 360

I-Mab Receives IND Approval from the US FDA to Initiate Clinical Trials for Its Proprietary TJC4, a Potential Global Best-in-Class Anti-CD47 Monoclonal Antibody

SHANGHAI, Jan. 28, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China -based clinical stage bio...

2019-01-28 21:58 297

I-Mab Biopharma Receives U.S. FDA IND Clearance for Proprietary CD73 Antibody TJD5

SHANGHAI, Jan. 22, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China -based clinical stage bio...

2019-01-22 22:04 267

I-Mab Receives U.S. FDA IND Approval for Proprietary Anti-GM-CSF Monoclonal Antibody TJM2

SHANGHAI, Dec. 23, 2018 /PRNewswire/ -- I-Mab Biopharma (I-Mab), a China-based clinical stage bioph...

2018-12-24 11:45 352

I-Mab and CSPC Pharma Announce Strategic Partnership for Long-acting GLP-1 Fc Program

SHANGHAI, Dec. 17, 2018 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China -based clinical stage bio...

2018-12-17 19:10 293

TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs

SHANGHAI, Nov. 29, 2018 /PRNewswire/ -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage bio...

2018-11-29 15:40 575

MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys's Novel Immuno-Oncology Agent MOR210

SHANGHAI, Nov. 15, 2018 /PRNewswire/ -- MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecD...

2018-11-16 05:01 410

I-Mab and Genexine Announce China IND Approval for Innovative Immunotherapy

SHANGHAI, Nov. 2, 2018 /PRNewswire/ -- I-MAB Biopharma Co., Ltd. ("I-Mab"), a Shanghai-based biotec...

2018-11-02 21:11 1041

First Patient Dosing achieved in Mainland China in a Phase II Multi-regional clinical trial (MRCT)

SHANGHAI, Oct. 12, 2018 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a company focusing on innovative...

2018-10-12 14:01 475

I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Three Bispecific Antibody Programs

SHANGHAI, Sept. 26, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access bio...

2018-09-26 21:27 585

I-Mab Wins Frost & Sullivan "2018 Best R&D Innovator Award (Biopharma Category)"

SHANGHAI, Sept. 19, 2018 /PRNewswire/ -- I-Mab Biopharma ("I-Mab") announced today that it has been...

2018-09-19 15:33 398

I-Mab's Announces China Clinical Trial Approval of Long-acting hGLP-1 to Treat Type 2 Diabetes

SHANGHAI, Aug. 9, 2018 /PRNewswire/ -- In July, 2018, I-Mab Biopharma (I-Mab) announced that it rec...

2018-08-09 16:16 406
12